Journal: Journal for Immunotherapy of Cancer

Article Title: Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release

doi: 10.1136/jitc-2025-013127

Figure Lengend Snippet: Lenalidomide boosts CD1d-Vδ2 bsTCE-triggered Vγ9Vδ2-T cell functions via CD28 phosphorylation and Notch signaling. ( A, B ) Vγ9Vδ2-T cell expansion ( A, n=3; B, n=10) after 7-day co-culture of PBMC with MM.1s.CD1d cells (ratio 10:1)±1 µM LEN, 10 nM CD1d-Vδ2 bsTCE, 10 µg/mL neutralizing human IL-2 antibody (αIL-2), and/or 100 IU/mL rhIL-2. ( C ) Representative histograms (n=3 independent experiments) depicting Tyr218 CD28 phosphorylation of Vγ9 + T cells in PBMC following 15-minute co-culture±10 nM CD1d-Vδ2 bsTCE and/or 1 µM LEN. ( D–E ) Vγ9Vδ2-T cell percentage (of total T cells) after 7-day co-culture ( D, n=14) and IL-2 secretion (fold change relative to CD1d-Vδ2 bsTCE condition) after 24 hours co-culture ( E, n=12) of PBMC with MM.1s.CD1d cells (ratio 10:1)±1 µM LEN, 10 nM CD1d-Vδ2 bsTCE, 10 µg/mL CTLA-4 Ig (abatacept). ( F ) qPCR analysis showing relative mRNA expression levels of Hes1 after 24 hours co-culture of expanded Vγ9Vδ2-T cells (purity >96%)±1 µM LEN. The 2–ΔΔCT method was applied to calculate the relative expression levels and normalized to GAPDH. n=3 in duplicate. ( G–J ) Vγ9Vδ2-T cell percentage (of total T cells) after 7-day co-culture ( G, n=12; I, n=12) and IL-2 secretion (fold change relative to CD1d-Vδ2 bsTCE condition) after 24 hours co-culture ( H, n=8; J , n=6) of PBMC with MM.1s.CD1d cells (ratio 10:1)±1 µM LEN, 10 nM CD1d-Vδ2 bsTCE, 10 µg/mL CTLA-4 Ig (abatacept), and/or 10 µM GSI (RO429097). Box-and-whisker plots indicate median, 25th–75th percentiles, and minimum−maximum. One-way ANOVA with Tukey’s multiple comparisons test ( B, D–I ), paired t-test ( F ). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. See also . ANOVA, analysis of variance; bsTCE, bispecific T-cell engagers; CTLA-4, cytotoxic T-lymphocyte associated protein 4; GSI, γ-secretase inhibitor; IL, interleukin; LEN, lenalidomide; MM, multiple myeloma; mRNA, messenger RNA; PBMC, peripheral blood mononuclear cells; qPCR, quantitative PCR.

Article Snippet: Where indicated, cells were cultured in the presence of rhIL-2 (100 IU/mL, Proleukin), neutralizing human IL-2 antibody (10 μg/mL, R&D Systems), abatacept (CTLA-4 Ig, 10 μg/mL, MedChemExpress), CB-103 (10 μg/mL, MedChemExpress), rapamycin (1 μM, MedChemExpress), or RO429097 (γ-secretase inhibitor (GSI), 10 μM, MedChemExpress).

Techniques: Phospho-proteomics, Co-Culture Assay, Expressing, Whisker Assay, Real-time Polymerase Chain Reaction

Journal: mAbs

Article Title: Optimizing human FcRn mouse models to improve pharmacokinetic evaluation of antibody drug candidates

doi: 10.1080/19420862.2026.2649990

Figure Lengend Snippet: Human FcRn transgene and zygosity affect ligand persistence. (A) Percent belatacept, ipilimumab, and pembrolizumab in plasma compared to concentrations 1 d post IV injection from ADA-free Tg32 hom, Tg32 hemi, Tg276 hom, Tg276 hemi, and FcRn null mice (10 mg/kg), (B) Half-life from ADA-free mice, (C) and allometric scaling of Tg32 hom clearance was correlated to human. (D) Trastuzumab plasma concentrations from IV dosed F1 mice (expressed both Tg32 hemi and Tg276 hemi) with transgenic controls (5 mg/kg), (E) and their trastuzumab half-lives using WinNonlin analysis except Tg276 hemi half-life was manually calculated from two timepoint concentrations. The values represent the mean ± SD. Statistical analysis was performed using either two-way ANOVA and Tukey’s multiple comparisons test, or one-way ANOVA Kruskal–Wallis test as appropriate, where p -values < 0.05 were considered statistically significant.

Article Snippet: All biologics formulated in this study–including pharmaceutical-grade belatacept (10 mg/kg), ipilimumab (10 mg/kg), pembrolizumab (10 mg/kg), trastuzumab (5 mg/kg and 10 mg/kg), etanercept (20 mg/kg), laboratory-grade glofitamab (MedChemExpress; 2 mg/kg), mosunetuzumab (MedChemExpress; 1 mg/kg), talquetamab (MedChemExpress; 1 mg/kg), conventional IgG monospecific antibody mAb-1 (proprietary source; 3 mg/kg and 10 mg/kg), and mAb-2 (proprietary source; 3 mg/kg and 10 mg/kg)–—were diluted prior to IV administration.

Techniques: Clinical Proteomics, IV Injection, Transgenic Assay

Journal: Pediatric Rheumatology Online Journal

Article Title: Proceedings of the 24 th Paediatric Rheumatology European Society Congress: Part two

doi: 10.1186/s12969-017-0186-9

Figure Lengend Snippet: See text for description

Article Snippet: Results: A total of 225 and 238 patients treated with IV abatacept, and 1346 and 1252 patients treated with other IV bDMARDs were identified in PharMetrics and MarketScan databases, respectively.

Techniques:

Journal: Pediatric Rheumatology Online Journal

Article Title: Proceedings of the 24 th Paediatric Rheumatology European Society Congress: Part two

doi: 10.1186/s12969-017-0186-9

Figure Lengend Snippet: See text for description

Article Snippet: Results: A total of 225 and 238 patients treated with IV abatacept, and 1346 and 1252 patients treated with other IV bDMARDs were identified in PharMetrics and MarketScan databases, respectively.

Techniques: